@thatsarajane's 5mg Mounjaro fears, fact-checked

What did @thatsarajane actually say?

She described completing four weeks on Mounjaro 5mg after dreading the dose increase, reporting mild side effects and inconsistent appetite suppression. Her main complaints were increased thirst and feeling "shivering cold" the day after injection, which she says happens at every dose. She also noted that the first two weeks worked as expected, but the second two weeks produced almost no appetite suppression and minimal weight loss.

This is a pretty grounded, low-drama account. She's not claiming dramatic results, not pushing a product, and she's openly describing a plateau-like experience mid-titration. That kind of honesty is genuinely useful in a space full of before-and-after hype. What she's describing, however, does raise some real pharmacological questions worth unpacking.

Does the science back this up?

Mostly, yes. The variable response she describes within a single dose tier is real and documented. Tirzepatide, the active ingredient in Mounjaro, has a half-life of roughly five days, meaning plasma levels fluctuate meaningfully across a weekly injection cycle. The cold sensitivity she reports is plausible and under-studied in public literature, but consistent with GLP-1 receptor activity affecting thermoregulation.

The SURPASS-1 trial (Rosenstock et al., 2021, JAMA) established that dose-response relationships with tirzepatide are not perfectly linear for every individual, and that intra-individual variability in appetite suppression is real. What @thatsarajane describes as "washy washy" suppression likely reflects that variability rather than treatment failure. Thirst is a reported but under-highlighted side effect, possibly linked to changes in fluid regulation and vasopressin signaling observed in GLP-1 receptor agonist research (Frias et al., 2022, New England Journal of Medicine).

What did they get wrong (or right)?

She got the lived experience mostly right, but her framing of the second two weeks as the drug "not doing anything at all" deserves scrutiny. Perceived appetite suppression and actual metabolic effect are not the same thing. Tirzepatide continues acting on glucose-dependent insulin secretion and gastric emptying even when subjective hunger feelings return. The drug doesn't simply switch off.

Her cold sensitivity claim is accurate as a personal observation but should not be taken as a universal side effect of the 5mg dose specifically. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) listed nausea, vomiting, and diarrhea as the most common adverse events, not cold chills. That doesn't mean her experience is false, it means it's idiosyncratic. Attributing it to the dose rather than the injection itself is something she actually handles correctly by noting it happens "with every jab no matter what."

What should you actually know?

If you're approaching a dose increase on tirzepatide, a few things are worth understanding that this video doesn't cover. First, weight loss variability across weeks is expected and does not reliably indicate whether the medication is working at a metabolic level. Second, "minimal losses" during titration are common and not a red flag. Third, the horror stories about dose escalation, while real for some people, are not the median experience. The SURMOUNT-4 trial data (Aronne et al., 2024, JAMA) suggests most people who escalate doses do so without discontinuing due to side effects.

The increased thirst she mentions warrants a note: staying well hydrated on GLP-1 and GIP receptor agonists is genuinely important, particularly because reduced food intake can reduce incidental fluid consumption. This is not a crisis, but it's worth tracking.

• Do not interpret fluctuating hunger as the drug failing between injections.
• Cold sensitivity post-injection is reported anecdotally but is not a primary documented side effect of 5mg specifically.
• Minimal weight loss during a titration period is clinically normal and expected.
• Any concerns about side effects or dose response should go to your prescribing clinician, not TikTok comment sections.